Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial

BACKGROUND & AIMS: Immunotherapy is an option for the treatment of advanced biliary tract cancer (BTC), although it has a low response rate. In this post hoc analysis, we investigated the predictive value of an immuno-genomic-radiomics (IGR) analysis for patients with BTC treated with camrelizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiu-Ping, Tang, Jie, Chen, Yi-Zhang, Guo, Fen, Ma, Ling, Pan, Lan-Lan, Tian, Yi-Tong, Wu, Xiao-Feng, Zhang, Yu-Dong, Chen, Xiao-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275977/
https://www.ncbi.nlm.nih.gov/pubmed/37333974
http://dx.doi.org/10.1016/j.jhepr.2023.100763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275977/
https://www.ncbi.nlm.nih.gov/pubmed/37333974
http://dx.doi.org/10.1016/j.jhepr.2023.100763

Ejemplares similares